Engasertib
Hereditary Hemorrhagic Telangiectasia (HHT)
Pre-clinicalActive
Key Facts
Indication
Hereditary Hemorrhagic Telangiectasia (HHT)
Phase
Pre-clinical
Status
Active
Company
About Vaderis Therapeutics
Vaderis Therapeutics is a private, clinical-stage biotech pioneering a first-in-class oral therapy for Hereditary Hemorrhagic Telangiectasia (HHT), a severe rare vascular disorder. The company's lead candidate, Engasertib, is a selective AKT1/2 inhibitor designed to correct the underlying vascular instability caused by HHT mutations. Backed by experienced leadership and venture capital investors like Medicxi and DROIA Ventures, Vaderis aims to address a significant unmet medical need in an underserved patient population. The company is currently in the clinical development phase, advancing its science from deep biological insight toward potential regulatory approval.
View full company profileTherapeutic Areas
Other Hereditary Hemorrhagic Telangiectasia (HHT) Drugs
| Drug | Company | Phase |
|---|---|---|
| AKT1 Program | Terremoto Biosciences | Pre-clinical |
| Undisclosed Program | Tectonic Therapeutic | Discovery |